DYRK2 and plasma cell myeloma: Furthermore, bortezomib-resistant RPMI8226 myeloma cells express higher protein levels of DYRK2 than nonresistant RPMI8226 (26), suggesting that DYRK2 might play a role in driving drug resistance in some myeloma cases.